Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06138613 · ClinicalTrials.gov registry record · Phase 3
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness
A Phase 3 study of Motion Sickness, sponsored by Vanda Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 705
- Enrollment target
- 1
- Study location
NCT06138613: Active Phase 3 study of Motion Sickness, sponsored by Vanda Pharmaceuticals.
NCT06138613 is a Phase 3 study of Motion Sickness that is active but no longer recruiting, run by Vanda Pharmaceuticals. The registered enrollment target is 705 participants, above the 38-participant average among 6 other Motion Sickness trials with a reported enrollment target (1755% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06138613, a Phase 3 study of Motion Sickness, is active but no longer recruiting, sponsored by Vanda Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 705 participants
- Enrollment target
- 1
- Study location
Study Summary
An open label study to investigate the safety and efficacy of tradipitant in participants affected by motion sickness during travel
Primary Outcome
Safety will be monitored using clinical measures, vital signs, blood chemistry, hematology, urology, and ECGs.
Conditions Studied
Interventions
- DRUG Tradipitant
Study Locations (1)
California
- Santa Monica Clinical Trials - Santa Monica
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 705 participants |
| Start Date | 2023-02-27 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 3 |
What the registry record for NCT06138613 still lists
NCT06138613 is an interventional study that assigns participants to a tested intervention. The registered 705 participants enrollment target is mid-sized for trials with a published cap, above the 38-participant average among 6 other Motion Sickness trials with a reported enrollment target (1755% higher).
The record links to 1 condition, with Motion Sickness appearing as the primary indexed condition, and to 1 intervention - of which Tradipitant is the first listed.
NCT06138613 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06138613 about?
NCT06138613 is a clinical study titled "Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness". An open label study to investigate the safety and efficacy of tradipitant in participants affected by motion sickness during travel
What is the current status of trial NCT06138613?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 705 participants. The study started on 2023-02-27. Estimated completion is 2026-06-30.
What conditions does trial NCT06138613 study?
This clinical trial studies the following conditions: Motion Sickness.
What interventions are being tested in trial NCT06138613?
The interventions under investigation include: Tradipitant (DRUG).
Who is sponsoring clinical trial NCT06138613?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06138613 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Motion Sickness
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
StableEyes With Active Neurofeedback
RECRUITING · NA
-
Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
RECRUITING · Phase 2
-
Evaluation of a Device to Reduce Motion Sickness and Spatial Disorientation
RECRUITING · NA
-
Three-Axis Wearable Adaptive Vestibular Stimulator
ACTIVE NOT RECRUITING · NA
-
Vestibulo-Ocular Reflex Function in Individuals With Chronic Motion Sensitivity Cross-Sectional Study
COMPLETED
-
Nebulizer Delivery of Intranasal Scopolamine
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06480383 · 705 participants · Phase 2
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
- NCT07067463 · 705 participants · Phase 3
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
- NCT05796687 · 704 participants · NA
Evaluation of My Future Self, an New Teen Pregnancy Prevention Group Intervention for Youth in Non-traditional Settings
- NCT06350734 · 704 participants
Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI